Biological and clinical implications of telomere dysfunction in myeloid malignancies

Therapeutic Advances in Hematology
Ashwin Kishtagari, Justin Watts

Abstract

Telomeres at the ends of linear chromosomes protect the genome. Telomeres shorten with each round of cell division, placing a finite limit on cell growth. Telomere attrition is associated with cell senescence and apoptosis. Telomerase, a specialized ribonucleoprotein complex, maintains telomeres homeostasis through repeat addition of telomere sequences to the 3' telomeric overhang. Telomere biology is closely related to cancer and normal aging. Upregulation of telomerase or activation of the alternative pathway of telomere lengthening is a hallmark of cancer cells, making telomerase an attractive target for cancer therapeutics. In this review, we will discuss telomere biology and the prognostic implications of telomere length in acute myeloid leukemia, and review exciting new investigational approaches using telomerase inhibitors in acute myeloid leukemia and other myeloid malignancies.

References

Jun 20, 1992·Journal of Molecular Biology·M Z LevyC B Harley
Oct 18, 1972·Nature: New Biology·J D Watson
Apr 1, 1997·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J W Shay, S Bacchetti
May 10, 2002·Nucleic Acids Research·Richard M Cawthon
Nov 11, 2003·Nature·Fabrizio d'Adda di FagagnaStephen P Jackson
Mar 11, 2004·Blood Reviews·Krzysztof MrózekClara D Bloomfield
Nov 11, 2005·Genes, Chromosomes & Cancer·Susan J J SwiggersJ Mark J M Zijlmans
Apr 5, 2007·Nature Protocols·Gabriela M BaerlocherPeter M Lansdorp
Jan 17, 2009·Proceedings of the National Academy of Sciences of the United States of America·Rodrigo T CaladoNeal S Young
Dec 8, 2009·Science·Titia de Lange
Feb 4, 2010·Nature Reviews. Molecular Cell Biology·Roderick J O'Sullivan, Jan Karlseder
Dec 13, 2012·Genome Biology·Matthew ParkerUNKNOWN Pediatric Cancer Genome Project
Feb 22, 2013·Leukemia·A M AalbersM M van den Heuvel-Eibrink
Sep 23, 2014·Blood·Danielle M TownsleyNeal S Young
Aug 25, 2015·Oncotarget·Mohamed Ali MosratiPeter Söderkvist
Sep 4, 2015·The New England Journal of Medicine·Ayalew TefferiAnimesh Pardanani
Sep 4, 2015·The New England Journal of Medicine·Gabriela M BaerlocherDavid S Snyder
Sep 4, 2015·The New England Journal of Medicine·Mary Armanios, Carol W Greider
Jun 30, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert B GerbingMaria M Gramatges
Sep 16, 2016·Acta Haematologica·Muhamed BaljevicMartin S Tallman
Jan 18, 2017·Nature Reviews. Molecular Cell Biology·John Maciejowski, Titia de Lange

❮ Previous
Next ❯

Citations

Jan 12, 2020·Current Topics in Medicinal Chemistry·Guilherme G da SilvaDiêgo M de Oliveira

❮ Previous
Next ❯

Methods Mentioned

BETA
MDS
flow
PCR
transgenic
xenograft

Clinical Trials Mentioned

NCT01243073
NCT01731951
NCT02598661
NCT02426086

Software Mentioned

IMbark

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Acute Myeloid Leukaemia & RNA

Acute myeloid leukaemia (AML) is a common hematological type of cancer. As the population ages, there has been a rise in the frequency of AML. RNA expression has been used to see if there are different genetic profiles that exist within AML and whether these may underpin the variations in survival rates. Here is the latest research on AML and RNA.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Related Papers

Frontiers in Bioscience (Scholar Edition)
Julieta PaneroIrma Slavutsky
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology
Kathryn L TerryDaniel W Cramer
© 2022 Meta ULC. All rights reserved